Left ventricular hypertrophy in normoalbuminuric type 2 diabetic patients not taking antihypertensive treatment

QJM: An International Journal of Medicine

Volumn 98, Issue 12, 2005, Pages 879-884

  Sato, A ^a   Tarnow, L ^a   Nielsen, F S ^a   Knudsen, E ^a   Parving, H H ^b  

^a STENO DIABETES CENTER   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; ORAL ANTIDIABETIC AGENT;

ADULT; AGE; ARTICLE; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE; BODY HEIGHT; BODY MASS; CARDIOVASCULAR RISK; CAUCASIAN; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIET THERAPY; DISEASE DURATION; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; LOGISTIC REGRESSION ANALYSIS; M MODE ECHOCARDIOGRAPHY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RISK FACTOR; SEX DIFFERENCE;

EID: 30444458525     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hci137     Document Type: Article

References (34)

1. Parving H-H, Mauer M, Ritz E. Diabetic Nephropathy. In: The Kidney, 7th edn. Philadelphia, WB Saunders, 2004:1777-818.
2. Nielsen FS, Voldsgaard AI, Gall M-A, Rossing P, Hommel E, Andersen P, et al. Apolipoprotein(a) and cardiovascular disease in type 2 (non-insulin-dependent) diabetic patients with and without diabetic nephropathy. Diabetologia 1993; 36:438-44.
3. Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003; 52:1210-14.
4. Vakili BA, Okin PM, Devereux RB. Prognostic implications of left ventricular hypertrophy. Am Heart J 2001; 141:334-41.
5. Verdecchia P, Angeli F, Borgioni C, Gattobigio R, de Simone G, Devereux RB, et al. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: A meta-analysis. Am J Hypertens 2003; 16:895-9.
6. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15:539-53.
7. Hother-Nielsen O, Faber O, Sørensen NS, Beck-Nielsen H. Classification of newly diagnosed diabetic patients as insulin-requiring or non-insulin-requiring based on clinical and biochemical variables. Diabetes Care 1988; 11:531-7.
8. Bendixen H, Holst C, Sørensen TI, Raben A, Bartels EM, Astrup A. Major increase in prevalence of overweight and obesity between 1987 and 2001 among Danish adults. Obes Res 2004; 12:1464-72.
9. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux RB, Feigenbaum H, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr 1989; 2:358-67.
10. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man: Anatomic validation of the method. Circulation 1977; 55:613-18.
11. de Simone G, Daniels SR, Devereux RB, Meyer RA, Roman MJ, et al. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. J Am Coll Cardiol 1992; 20:1251-60.
12. Savage DD, Garrison RJ, Kannel WB, Levy D, Anderson SJ, Strokes III J, et al. The spectrum of left ventricular hypertrophy in a general population sample: The Framingham study. Circulation 1987; 75(suppl. 1):1-26.
13. Devereux RB, Lutas EM, Casale PN, Kligfield P, Eisenberg RR, Hammond IW, et al. Standardization of M-mode echocardiographic left ventricular anatomic measurements. J Am Coll Cardiol 1984; 4:1222-30.
14. Ganau A, Devereux RB, Roman MJ, de Simone G, Pickering TG, Saba PS, et al. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol 1992; 19:1550-8.
15. Feldt-Rasmussen B, Dinesen B, Deckert M. Enzyme immunoassay: An improved determination of urinary albumin in diabetics with incipient nephropathy. Scand J Clin Lab Invest 1985; 45:539-44.
16. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham study. N Engl J Med 1990; 322:1561-6.
17. Galderisi M, Anderson KM, Wilson PWF, Levy D. Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (The Framingham heart study). Am J Cardiol 1991; 68:85-9.
18. Struthers AD, Morris AD. Screening for and treating left ventricular abnormalities in diabetes mellitus: A new way of reducing cardiac deaths. Lancet 2002; 359:1430-2.
19. Devereux RB, Roman MJ, Paranicas M, O'Grady MJ, Lee ET, Welty TK, et al. Impact of diabetes on cardiac structure and function: The Strong Heart Study. Circulation 2000; 101:2271-6.
20. Bruno G, Giunti S, Bargero G, Ferrero S, Pagano G, Cavallo-Perin P. Sex-differences in prevalence of electrocardiographic left ventricular hypertrophy in Type 2 diabetes: The Casale Monferrato Study. Diabet Med 2004; 21:823-8.
21. Grossman E, Shemesh J, Shamiss A, Tahler M, Carroll J, Rosenthal T. Left ventricular mass in diabetes-hypertension. Arch Intern Med 1992; 152:1001-4.
22. Palmieri V, Bella JN, Arnett DK, Liu JE, Oberman A, Schuck M-Y, et al. Effect of type 2 diabetes mellitus on left ventricular geometry and systolic function in hypertensive subjects - Hypertension Genetic Epidemiology Network (HyperGEN) Study. Circulation 2001; 103:102-7.
23. Guidelines subcommittee of the WHO/ISH mild hypertension liaison committee. Guidelines for the management of mild hypertension: memorandoum from the World Health Organization/International Society of Hypertension meeting. J Hypertens 1993; 11:905-18.
24. Joint National Committee on Detection Evaluation Treatment of High Blood Pressure. The fifth report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNC-V). Arch Intern Med 1993; 153:154-83.
25. Fesler P, du Cailar G, Ribstein J, Mimran A. Left ventricular remodeling and renal function in never-treated essential hypertension. J Am Soc Nephrol 2003; 14:881-7.
26. Sato A, Tarnow L, Parving H-H. Prevalence of left ventricular hypertrophy in type 1 diabetic patients with diabetic nephropathy. Diabetologia 1999; 42:76-80.
27. Nielsen FS, Ali S, Rossing P, Bang LE, Svendsen TL, Gall M-A, et al. Left ventricular hypertrophy in non-insulin dependent diabetic patients with and without diabetic nephropathy. Diabetic Med 1997; 14:538-46.
28. Rutter MK, McComb JM, Forster J, Brady S, Marshall SM. Increased left ventricular mass index and nocturnal systolic blood pressure in patients with type 2 diabetes mellitus and microalbuminuria. Diabet Med 2000; 17:321-5.
29. Wachtell K, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: The LIFE study. Ann Intern Med 2003; 139: 901-6.
30. Lauer MS, Anderson KM, Kannel WB, Levy D. The impact of obesity on left ventricular mass and geometry. JAMA 1991; 226:231-6.
31. Felicio JS, Ferreira SR, Plavnik FL, Moises V, Kohlmann O Jr., Ribeiro AB, et al. Effect of blood glucose on left ventricular mass in patients with hypertension and type 2 diabetes mellitus. Am J Hypertens 2000; 13:1149-54.
32. Cecchi F, Olivotto I, Gistri R, Lorenzoni R, Chiriatti G, Camici PG. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med 2003; 349:1027-35.
33. Wanner C. C-reactive protein risk prediction: Adding cardiac hypertrophy to the list. Am J Kidney Diseases 2002; 40:1340-1.
34. Zuraw B. Bradykinin in protection against left ventricular hypertrophy. Lancet 2001; 358:1116-18.